Eli Lilly (LLY) believes its experimental weight-loss pill could make GLP-1 treatments more accessible worldwide.
We believe there is minimal cause for concern with LLY stock, which makes it attractive but highly sensitive to adverse ...
Eli Lilly (LLY), the maker of the blockbuster weight-loss drug Zepbound, launched a new advertising campaign on Friday ...
The company is doubling plans for capital spending on U.S. factories as President Donald Trump pressures the pharma industry ...
Shares of Eli Lilly & Co. LLY slid 4.73% to $869.58 Friday, on what proved to be an all-around positive trading session for ...
Morgan Stanley analyst Terence Flynn notes that Novo Nordisk (NVO) reported CagriSema Phase 3 data in type two diabetes demonstrating weight ...
Hosted on MSN21d
Eli Lilly wants to use its weight loss drug windfall to fight Alzheimer's and hearing lossMedical bottles and syringe are seen with Eli Lilly and Company logo displayed on a screen in the background in this illustration photo taken in Krakow, Poland on November 10, 2022. The weight ...
A study in people with obesity and diabetes again found CagriSema helps people lose weight, but not by enough to clearly ...
MariTide is a monthly injection that investors hope could compete against existing weight loss drugs from Novo Nordisk and ...
Eli Lilly and Co. Wednesday announced plans to build four pharmaceutical manufacturing sites in the United States, significantly boosting domestic medicine production and adding around 13,000 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback